- Home
- APVO vs LPCN Comparison
APVO vs LPCN Comparison
Compare APVO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- LPCN
- Stock Information
- Founded
- APVO 2016
- LPCN 1997
- Country
- APVO United States
- LPCN United States
- Employees
- APVO N/A
- LPCN N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- LPCN Health Care
- Exchange
- APVO Nasdaq
- LPCN Nasdaq
- Market Cap
- APVO 21.7M
- LPCN 18.2M
- IPO Year
- APVO N/A
- LPCN N/A
- Fundamental
- Price
- APVO $1.46
- LPCN $2.75
- Analyst Decision
- APVO
- LPCN Strong Buy
- Analyst Count
- APVO 0
- LPCN 1
- Target Price
- APVO N/A
- LPCN $8.00
- AVG Volume (30 Days)
- APVO 4.5M
- LPCN 59.3K
- Earning Date
- APVO 11-10-2025
- LPCN 11-07-2025
- Dividend Yield
- APVO N/A
- LPCN N/A
- EPS Growth
- APVO N/A
- LPCN N/A
- EPS
- APVO N/A
- LPCN N/A
- Revenue
- APVO N/A
- LPCN $4,208,119.00
- Revenue This Year
- APVO N/A
- LPCN N/A
- Revenue Next Year
- APVO N/A
- LPCN N/A
- P/E Ratio
- APVO N/A
- LPCN N/A
- Revenue Growth
- APVO N/A
- LPCN N/A
- 52 Week Low
- APVO $1.32
- LPCN $2.65
- 52 Week High
- APVO $298.00
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- APVO 42.13
- LPCN 38.39
- Support Level
- APVO $1.48
- LPCN $2.75
- Resistance Level
- APVO $1.57
- LPCN $2.92
- Average True Range (ATR)
- APVO 0.09
- LPCN 0.14
- MACD
- APVO 0.00
- LPCN -0.04
- Stochastic Oscillator
- APVO 0.00
- LPCN 6.12
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.